Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 13;8(15):4144-4148.
doi: 10.1182/bloodadvances.2024013248.

T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy

Lisa J Martin  1 , James B Whitmore  1 , Rhine R Shen  1 , Frank Neumann  1
Affiliations

T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy

Lisa J Martin et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: L.J.M. reports employment at Kite, a Gilead company; and stock or other ownership in Gilead Sciences. J.B.W. reports employment with Kite, a Gilead company; and stock or other ownership in Gilead Sciences. R.R.S. reports employment with Kite, a Gilead company; stock or other ownership in Gilead Sciences; and patents, royalties, and other intellectual property from Atara and Kite. F.N. reports former employment with Kite, a Gilead company; stock or other ownership in bluebird bio, Gilead Sciences, and 2seventy bio; and other relationship with Kite.

References

    1. US Food and Drug Administration. FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologi... 28 November 2023.
    1. Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148–157. - PubMed
    1. Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555–567. - PMC - PubMed
    1. Chihara D, Dores GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood. 2021;138(9):785–789. - PMC - PubMed
    1. Ghilardi G, Fraietta JA, Gerson JN, et al. T-cell lymphoma and secondary primary malignancy risk after commercial CAR T-cell therapy. Nat Med. 2024;30(4):984–989. - PubMed

Publication types

MeSH terms